Matthew J. Molloy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Matthew J. Molloy has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Michael J. Steiner
Department of Pediatrics Oklahoma University College of Medicine Oklahoma City Oklahoma USA
9 shared publicationsElisha McCoy
Department of Pediatrics, Le Bonheur Children′s Hospital University of Tennessee Health Science Center Memphis Tennessee USA
7 shared publications- Jessica L. Markham
Department of Pediatrics, Children's Mercy Kansas City University of Missouri‐Kansas City School of Medicine Kansas City Missouri USA
7 shared publications - Jillian Mayer Cotter
Section of Hospital Medicine, Children's Hospital Colorado, Department of Pediatrics University of Colorado Aurora Colorado USA
7 shared publications - Matt Hall
Children's Hospital Association Lenexa Kansas USA
7 shared publications - Michael J. Tchou
Department of Pediatrics Children's Hospital Colorado and University of Colorado School of Medicine Aurora Colorado USA
7 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Wiley in Journal of Hospital Medicine
Racial and ethnic differences in hospital‐based low‐value pediatric care
Background: Low‐value care (LVC), or care in which potential risk outweighs perceived benefits, continues to impact pediatric populations. While pediatric healthcare delivery is known to vary across racial and ethnic groups, little is known about the relationship between race and ethnicity and LVC. We sought to evaluate this relationship among hospitalized children. Methods: This cross‐sectional study applied the Pediatric Health Information System LVC Calculator to encounters from July 1, 2022 to June 30, 2024. We used generalized estimating equation models to analyze differences in LVC across seven groups (Non‐Hispanic White, Non‐Hispanic Black, Hispanic, Asian, American Indian or Alaska Native, Native Hawaiian or Pacific Islander, and Other or Multiracial). For measures with across‐group differences, we performed pairwise comparisons to assess differential odds of LVC receipt with the Non‐Hispanic White group as a referent. We then performed a subanalysis applying these methods to only the largest groups. Results: Of 14 eligible measures, LVC varied across racial and ethnic groups for seven. Patterns varied by measure, with no group demonstrating consistently high or low LVC. Measures with the greatest variation across groups included head computed tomography for first seizure, concurrent use of antipsychotics, and broad‐spectrum antibiotics for uncomplicated community‐acquired pneumonia. Our subanalysis demonstrated similar findings, with across‐group differences noted for eight measures. Conclusions: We identified differences in LVC receipt by race and ethnicity for some services among hospitalized patients, without consistency in patterns across measures. Further evaluation of drivers and outcomes associated with these patterns is needed; our findings may assist in prioritizing deimplementation efforts.
- 22 September 2026
- Published by Wiley in Journal of Hospital Medicine
Open AccessRacial and ethnic differences in hospital‐based low‐value pediatric care
Background: Low‐value care (LVC), or care in which potential risk outweighs perceived benefits, continues to impact pediatric populations. While pediatric healthcare delivery is known to vary across racial and ethnic groups, little is known about the relationship between race and ethnicity and LVC. We sought to evaluate this relationship among hospitalized children. Methods: This cross‐sectional study applied the Pediatric Health Information System LVC Calculator to encounters from July 1, 2022 to June 30, 2024. We used generalized estimating equation models to analyze differences in LVC across seven groups (Non‐Hispanic White, Non‐Hispanic Black, Hispanic, Asian, American Indian or Alaska Native, Native Hawaiian or Pacific Islander, and Other or Multiracial). For measures with across‐group differences, we performed pairwise comparisons to assess differential odds of LVC receipt with the Non‐Hispanic White group as a referent. We then performed a subanalysis applying these methods to only the largest groups. Results: Of 14 eligible measures, LVC varied across racial and ethnic groups for seven. Patterns varied by measure, with no group demonstrating consistently high or low LVC. Measures with the greatest variation across groups included head computed tomography for first seizure, concurrent use of antipsychotics, and broad‐spectrum antibiotics for uncomplicated community‐acquired pneumonia. Our subanalysis demonstrated similar findings, with across‐group differences noted for eight measures. Conclusions: We identified differences in LVC receipt by race and ethnicity for some services among hospitalized patients, without consistency in patterns across measures. Further evaluation of drivers and outcomes associated with these patterns is needed; our findings may assist in prioritizing deimplementation efforts.
- Open Access
- 10 September 2026
- Published by Wiley in Journal of Hospital Medicine
Variation in blood culture testing in children hospitalized with three common infections
Background: Routine blood culture (BCx) testing in uncomplicated community‐acquired pneumonia (CAP), skin and soft tissue infections (SSTI), and urinary tract infections (UTI) has demonstrated low clinical utility. Objectives: To evaluate hospital‐level BCx testing trends and their association with clinical outcomes for children hospitalized with CAP, SSTI, and UTI. Methods: This retrospective cohort study used the Pediatric Health Information System database to identify hospitalizations of children aged 3 months–18 years with CAP, SSTI, and UTI from 2016 to 2024. We excluded patients with complicated infections, complex chronic conditions, intensive care unit admission, or length of stay (LOS) > 7 days. Hospital‐level BCx testing rates were calculated by infection type, and annual trends were examined. Hospitals were grouped into low, moderate, and high BCx testing groups. Outcomes including LOS, costs, readmissions, and emergency department revisits were compared across hospital groups, adjusting for infection type, age, and illness severity. Results: Among 133,783 encounters across 37 hospitals, BCxs were obtained in 42% hospitalizations for CAP, 46% for SSTI, and 56% for UTI hospitalizations with substantial hospital‐level variation (e.g., 14%–77% for CAP). Over time, four hospitals showed significant increases, eight showed decreases, and 25 showed no change in annual BCx testing. No clinically significant differences in outcomes were observed across low ( n = 15), moderate ( n = 14), or high ( n = 8) hospital testing groups. Conclusions: BCx testing remains frequent for CAP, SSTI, and UTI with a minority of hospitals demonstrating testing reductions over time. The frequency of BCx testing and lack of significant differences in outcomes suggests opportunities for diagnostic stewardship.
- 10 September 2026
- Published by Wiley in Journal of Hospital Medicine
Open AccessVariation in blood culture testing in children hospitalized with three common infections
Background: Routine blood culture (BCx) testing in uncomplicated community‐acquired pneumonia (CAP), skin and soft tissue infections (SSTI), and urinary tract infections (UTI) has demonstrated low clinical utility. Objectives: To evaluate hospital‐level BCx testing trends and their association with clinical outcomes for children hospitalized with CAP, SSTI, and UTI. Methods: This retrospective cohort study used the Pediatric Health Information System database to identify hospitalizations of children aged 3 months–18 years with CAP, SSTI, and UTI from 2016 to 2024. We excluded patients with complicated infections, complex chronic conditions, intensive care unit admission, or length of stay (LOS) > 7 days. Hospital‐level BCx testing rates were calculated by infection type, and annual trends were examined. Hospitals were grouped into low, moderate, and high BCx testing groups. Outcomes including LOS, costs, readmissions, and emergency department revisits were compared across hospital groups, adjusting for infection type, age, and illness severity. Results: Among 133,783 encounters across 37 hospitals, BCxs were obtained in 42% hospitalizations for CAP, 46% for SSTI, and 56% for UTI hospitalizations with substantial hospital‐level variation (e.g., 14%–77% for CAP). Over time, four hospitals showed significant increases, eight showed decreases, and 25 showed no change in annual BCx testing. No clinically significant differences in outcomes were observed across low ( n = 15), moderate ( n = 14), or high ( n = 8) hospital testing groups. Conclusions: BCx testing remains frequent for CAP, SSTI, and UTI with a minority of hospitals demonstrating testing reductions over time. The frequency of BCx testing and lack of significant differences in outcomes suggests opportunities for diagnostic stewardship.
- Open Access
- 27 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Bytes to Bedside: Protocol for a Multi-Site Mixed-Methods Study for Development and Evaluation of a Collaborative Framework for Clinical Decision Support Evaluation (Preprint)
BACKGROUND Clinical Decision Support (CDS) systems are crucial for translating research findings into clinical practice. However, the effectiveness of CDS varies significantly, and a comprehensive evaluation framework is necessary to predict successful implementation. This study aims to address these gaps through a collaborative effort to standardize CDS evaluation across multiple sites. OBJECTIVE The objectives of this study are to (1) develop an evaluation framework for CDS across collaboration sites and (2) determine whether a collaborative CDS analytics platform improves CDS evaluation efficiency and completeness. METHODS Leveraging the EPIS (Exploration, Preparation, Implementation, Sustainment) framework, we will establish a multi-site collaborative framework for CDS evaluation. This study will develop a common evaluation framework and an innovative CDS analytics platform. Our mixed-methods approach includes forming a governance structure and workgroups to facilitate collaboration and using a modified Delphi process to develop a consensus approach to pragmatic CDS evaluation. We will then conduct a randomized, incomplete block design study to compare the efficiency and completeness of CDS evaluations across collaborating and non-collaborating sites. RESULTS As of August, 2026, the pediatric CDS collaborative includes 20 health systems and has been formalizing governance structures and standing committees. During the UG3 phase, we anticipate completing selection of eight representative CDS use cases, developing a consensus CDS evaluation framework, and designing and usability-testing a CDS evaluation dashboard and centralized analytics platform. No outcome data are available at this stage. CONCLUSIONS By establishing a standardized evaluation framework and a centralized analytics platform, the collaborative seeks to transform CDS design into a predictive science. This initiative will provide a scalable model for CDS evaluation, facilitating the rapid translation of research evidence into clinical practice across diverse healthcare settings.
- 27 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessBytes to Bedside: Protocol for a Multi-Site Mixed-Methods Study for Development and Evaluation of a Collaborative Framework for Clinical Decision Support Evaluation (Preprint)
BACKGROUND Clinical Decision Support (CDS) systems are crucial for translating research findings into clinical practice. However, the effectiveness of CDS varies significantly, and a comprehensive evaluation framework is necessary to predict successful implementation. This study aims to address these gaps through a collaborative effort to standardize CDS evaluation across multiple sites. OBJECTIVE The objectives of this study are to (1) develop an evaluation framework for CDS across collaboration sites and (2) determine whether a collaborative CDS analytics platform improves CDS evaluation efficiency and completeness. METHODS Leveraging the EPIS (Exploration, Preparation, Implementation, Sustainment) framework, we will establish a multi-site collaborative framework for CDS evaluation. This study will develop a common evaluation framework and an innovative CDS analytics platform. Our mixed-methods approach includes forming a governance structure and workgroups to facilitate collaboration and using a modified Delphi process to develop a consensus approach to pragmatic CDS evaluation. We will then conduct a randomized, incomplete block design study to compare the efficiency and completeness of CDS evaluations across collaborating and non-collaborating sites. RESULTS As of August, 2026, the pediatric CDS collaborative includes 20 health systems and has been formalizing governance structures and standing committees. During the UG3 phase, we anticipate completing selection of eight representative CDS use cases, developing a consensus CDS evaluation framework, and designing and usability-testing a CDS evaluation dashboard and centralized analytics platform. No outcome data are available at this stage. CONCLUSIONS By establishing a standardized evaluation framework and a centralized analytics platform, the collaborative seeks to transform CDS design into a predictive science. This initiative will provide a scalable model for CDS evaluation, facilitating the rapid translation of research evidence into clinical practice across diverse healthcare settings.
- 3 August 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (8) , 96-98
Sound Governance of Vendor-Created Generative AI Tools Requires Collective Action
Char et al. (2026) describe their use of stakeholder interviewing to conduct ethical assessments of generative artificial intelligence (AI) applications that summarize clinical information. This is...
- 3 August 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (8) , 96-98
Sound Governance of Vendor-Created Generative AI Tools Requires Collective Action
Char et al. (2026) describe their use of stakeholder interviewing to conduct ethical assessments of generative artificial intelligence (AI) applications that summarize clinical information. This is...
- 29 July 2026
- Published by Wiley in Journal of Hospital Medicine
- Vol. 21 (9) , 1087-1088
Beyond the pager: Rethinking trainee workload in the era of clinical messaging
- 29 July 2026
- Published by Wiley in Journal of Hospital Medicine
- Vol. 21 (9) , 1087-1088
Beyond the pager: Rethinking trainee workload in the era of clinical messaging
- Open Access
- 25 October 2025
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 25 (1) , 1-9
Using the Electronic Health Record to Facilitate Drug Allergy Delabeling
Purpose of Review: There is a growing number of allergy delabeling programs across diverse clinical specialties and care settings. The electronic health record (EHR) can be leveraged to facilitate allergy delabeling. The purpose of this review is to describe EHR tools that have been used in allergy delabeling programs. We also provide recommendations for organizations considering EHR-based allergy delabeling workflows that incorporate clinical informatics best practices. Recent Findings: Recent literature describes several EHR tools used in delabeling. These tools can be organized around the steps of the allergy delabeling workflow: 1. Identify eligible patients, 2. Risk stratify, 3. Evaluation and testing, 4. Documentation of outcome, 5. Delabeling, and 6. Allergy label reconciliation. Summary: Standardized EHR tools across the allergy delabeling workflow can lead to successful delabeling and support of diverse stakeholders. Partnering with EHR vendors presents an opportunity to make these tools readily available and improve allergy documentation.
- 25 October 2025
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 25 (1) , 1-9
Open AccessUsing the Electronic Health Record to Facilitate Drug Allergy Delabeling
Purpose of Review: There is a growing number of allergy delabeling programs across diverse clinical specialties and care settings. The electronic health record (EHR) can be leveraged to facilitate allergy delabeling. The purpose of this review is to describe EHR tools that have been used in allergy delabeling programs. We also provide recommendations for organizations considering EHR-based allergy delabeling workflows that incorporate clinical informatics best practices. Recent Findings: Recent literature describes several EHR tools used in delabeling. These tools can be organized around the steps of the allergy delabeling workflow: 1. Identify eligible patients, 2. Risk stratify, 3. Evaluation and testing, 4. Documentation of outcome, 5. Delabeling, and 6. Allergy label reconciliation. Summary: Standardized EHR tools across the allergy delabeling workflow can lead to successful delabeling and support of diverse stakeholders. Partnering with EHR vendors presents an opportunity to make these tools readily available and improve allergy documentation.
- 9 October 2025
- Published by Wiley in Journal of Hospital Medicine
- Vol. 21 (4) , 380-390
Frequency, cost, and variation in inpatient diagnostic imaging use in children′s hospitals
Background: Diagnostic imaging studies are frequently utilized when caring for pediatric patients. The most prevalent and costly imaging studies among hospitalized children are unknown. Objective: Identify imaging studies with highest frequency, cost, rates of repetition, and hospital variation among hospitalized children, including patients with intensive care (ICU) stays and complex chronic conditions (CCCs). Methods: We performed a retrospective cohort study of patients hospitalized from January 1, 2021 to December 31, 2022 across 45 children′s hospitals in the Pediatric Health Information System. We identified diagnostic imaging studies for inpatient and observation encounters using billing codes grouped by body system and modality. We measured imaging frequency, costs, and variation across hospitals, overall and for ICU stays and children with CCCs. Results: We identified 1,523,343 encounters; 59.1% had imaging, with $2.03 billion in imaging costs. The most frequently obtained and repeated imaging included chest X‐ray (CXR), abdominal X‐ray, and cardiovascular (CV) ultrasound/echocardiography. The imaging studies with highest cumulative cost were cardiovascular ultrasound, CXR, and neuro/head MRI. ICU encounters were 15.1% of total encounters, but accounted for 44.6% of imaging costs; CCC encounters were 39.6% of the total but accounted for 74.2% of costs. Interhospital variation was low among the most frequent and costly imaging modalities. Conclusions: Among a cohort of hospitalized children, CXR and CV ultrasounds were among the most prevalent, costly, and frequently repeated imaging studies. Encounters with ICU stays and for patients with CCCs incurred disproportionate imaging costs. Our results serve as a starting point for identifying imaging overuse and developing achievable benchmarks of care.
- 9 October 2025
- Published by Wiley in Journal of Hospital Medicine
- Vol. 21 (4) , 380-390
Frequency, cost, and variation in inpatient diagnostic imaging use in children′s hospitals
Background: Diagnostic imaging studies are frequently utilized when caring for pediatric patients. The most prevalent and costly imaging studies among hospitalized children are unknown. Objective: Identify imaging studies with highest frequency, cost, rates of repetition, and hospital variation among hospitalized children, including patients with intensive care (ICU) stays and complex chronic conditions (CCCs). Methods: We performed a retrospective cohort study of patients hospitalized from January 1, 2021 to December 31, 2022 across 45 children′s hospitals in the Pediatric Health Information System. We identified diagnostic imaging studies for inpatient and observation encounters using billing codes grouped by body system and modality. We measured imaging frequency, costs, and variation across hospitals, overall and for ICU stays and children with CCCs. Results: We identified 1,523,343 encounters; 59.1% had imaging, with $2.03 billion in imaging costs. The most frequently obtained and repeated imaging included chest X‐ray (CXR), abdominal X‐ray, and cardiovascular (CV) ultrasound/echocardiography. The imaging studies with highest cumulative cost were cardiovascular ultrasound, CXR, and neuro/head MRI. ICU encounters were 15.1% of total encounters, but accounted for 44.6% of imaging costs; CCC encounters were 39.6% of the total but accounted for 74.2% of costs. Interhospital variation was low among the most frequent and costly imaging modalities. Conclusions: Among a cohort of hospitalized children, CXR and CV ultrasounds were among the most prevalent, costly, and frequently repeated imaging studies. Encounters with ICU stays and for patients with CCCs incurred disproportionate imaging costs. Our results serve as a starting point for identifying imaging overuse and developing achievable benchmarks of care.
- Open Access
- 3 March 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (3) , e250160
Trends in Respiratory Pathogen Testing at US Children’s Hospitals
Importance: Respiratory pathogen testing has been a common deimplementation focus. The COVID-19 pandemic brought new considerations for respiratory testing; recent trends in testing rates are not well understood.Objective: To measure trends in respiratory testing among encounters for acute respiratory infections among children and adolescents (aged P < .001) and hospitalizations (slope, 0.12 [95% CI, 0.07-0.16]; P < .001). Increases in respiratory testing were seen at the onset of the COVID-19 pandemic in both ED-only encounters (level change, 33.78 [95% CI, 31.77-35.79]; P < .001) and hospitalizations (level change, 30.97 [95% CI, 29.21-32.73]; P < .001), associated initially with COVID-19–only testing. Postpandemic testing rates remained elevated relative to prepandemic levels. The percentage of encounters with respiratory testing increased from 13.6% [95% CI, 13.5%-13.7%] in 2016 to a peak of 62.2% [95% CI, 62.1%-62.3%] in 2022. While COVID-19–only testing decreased after 2020, other targeted testing and large-panel (>5 targets) testing increased. The inflation-adjusted standardized unit cost associated with respiratory testing increased from $34.2 [95% CI, $33.9-$34.6] per encounter in 2017 to $128.2 [95% CI, $127.7-$128.6] per encounter in 2022.Conclusions and Relevance: The findings of this cross-sectional study suggest that respiratory testing rates have increased over time, with large increases at the onset of the COVID-19 pandemic that have persisted. Respiratory testing rates and related costs increased significantly, supporting a need for future deimplementation efforts.
- 3 March 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (3) , e250160
Open AccessTrends in Respiratory Pathogen Testing at US Children’s Hospitals
Importance: Respiratory pathogen testing has been a common deimplementation focus. The COVID-19 pandemic brought new considerations for respiratory testing; recent trends in testing rates are not well understood.Objective: To measure trends in respiratory testing among encounters for acute respiratory infections among children and adolescents (aged P < .001) and hospitalizations (slope, 0.12 [95% CI, 0.07-0.16]; P < .001). Increases in respiratory testing were seen at the onset of the COVID-19 pandemic in both ED-only encounters (level change, 33.78 [95% CI, 31.77-35.79]; P < .001) and hospitalizations (level change, 30.97 [95% CI, 29.21-32.73]; P < .001), associated initially with COVID-19–only testing. Postpandemic testing rates remained elevated relative to prepandemic levels. The percentage of encounters with respiratory testing increased from 13.6% [95% CI, 13.5%-13.7%] in 2016 to a peak of 62.2% [95% CI, 62.1%-62.3%] in 2022. While COVID-19–only testing decreased after 2020, other targeted testing and large-panel (>5 targets) testing increased. The inflation-adjusted standardized unit cost associated with respiratory testing increased from $34.2 [95% CI, $33.9-$34.6] per encounter in 2017 to $128.2 [95% CI, $127.7-$128.6] per encounter in 2022.Conclusions and Relevance: The findings of this cross-sectional study suggest that respiratory testing rates have increased over time, with large increases at the onset of the COVID-19 pandemic that have persisted. Respiratory testing rates and related costs increased significantly, supporting a need for future deimplementation efforts.
- 26 February 2025
- Published by Wiley in Journal of Hospital Medicine
- Vol. 20 (9) , 1015-1017
Secure messaging in medical training: Carving a path for trainee development in the digital age
- 26 February 2025
- Published by Wiley in Journal of Hospital Medicine
- Vol. 20 (9) , 1015-1017
Secure messaging in medical training: Carving a path for trainee development in the digital age
- 30 August 2024
- Published by Wiley in Journal of Hospital Medicine
- Vol. 20 (1) , 96-97
Using patient preferences to shift healthcare culture: Patient‐centered clinical decision support as a tool to aid in hospital at home participation
- 30 August 2024
- Published by Wiley in Journal of Hospital Medicine
- Vol. 20 (1) , 96-97
Using patient preferences to shift healthcare culture: Patient‐centered clinical decision support as a tool to aid in hospital at home participation